I'll then provide a financial overview and comments with respect to our cash position, details on our investments in research and development activities, as well as updated financial guidance for 2012.Robert will then conclude the call with additional comments regarding recent activities and expected next steps for our development stage programs as well as an update regarding projected company milestones for the remainder of 2012. We will then open the call for a brief question and answer session. The following discussion including our responses to questions contain statements that constitute forward-looking statements for the purposes of the Safe Harbor provisions of the private securities litigation reform act of 1995. Including but not limited to statements relating to our financial guidance, to the initiation enrollment designed conduct and results of clinical trials, and to other research and development activities. Our actual results might differ materially from those projected in these forward-looking statements. Additional information concerning factors that could cause our actual results to differ materially from those forward-looking statements is contained in our SEC filings including our most recent annual report on form 10-K, our quarterly reports on form 10-Q, and our current reports on form AK. Copies of these documents may be obtained from the SEC or by visiting the investor relations section of our website. These forward-looking statements speak only as of today. You should not rely on them as representing our views in the future. And we undertake no obligation to update these statements after this call. Now I'll turn the call over to Robert. Robert Blum Thank you, Sharon. During the second quarter, we took important steps to insure that we continue to build on the progress reported in the first quarter. And remain focused to key value driving milestones. In recent months, we have received notifications of each of the United States adopted names or USA End Council and the World Health Organizations Consultation on International Non-Proprietary Names for pharmaceutical substances program that indicated the adoption of tirasemtiv as the generic name for CK-2017357. Going forward and on this call today, we will use the newly adopted generic name tirasemtiv when referring to the lead development compound in our skeletal muscle activator program directed to the potential treatment of Amyotrophic lateral sclerosis or ALS.